Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Invitrogen™ CD134 (OX40) Monoclonal Antibody (OX-86), Super Bright™ 780, eBioscience™, Invitrogen™

Rat Monoclonal Antibody

Supplier:  Invitrogen™ 78134182

Encompass_Preferred

 View more versions of this product

Catalog No. 78-134-182


Only null left
Add to Cart

Description

Description

Description: This 1RNM44N monoclonal antibody recognizes mouse CD170, also known as Siglec F. Siglec F is a cell surface lectin belonging to the Ig superfamily that binds glycoconjugates containing sialic acids that are commonly found on various cell types. The cytoplasmic domain of Siglec F contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) that initiates intracellular signaling upon ligand binding. Siglec F is expressed mostly on eosinophils and alveolar macrophages and lower levels of this receptor have also been reported on immature myelomonocytic cells. Mouse Siglec F is a functional ortholog of human Siglec 8, however, unlike human Siglec 8, mouse Siglec F is not expressed on mast cells. This 1RNM44N antibody will recognize a formaldehyde-fixed epitope. Applications Reported: This 1RNM44N antibody has been reported for use in flow cytometric analysis. Applications Tested: This 1RNM44N antibody has been tested by flow cytometric analysis of mouse thioglycolate-elicited peritoneal exudate cells. This can be used at less than or equal to 0.5 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

OX40 is a protein receptor found on the surface of T cells, a type of white blood cell that plays a crucial role in the immune system. When activated, OX40 promotes the proliferation and survival of T cells, leading to a stronger immune response against cancer cells and infectious agents. OX40 agonists, which are drugs that activate OX40, have shown promising results in preclinical and clinical studies as a potential immunotherapy for cancer. They can enhance the efficacy of other cancer treatments such as chemotherapy and checkpoint inhibitors, and may also have applications in autoimmune diseases and allergies.
TRUSTED_SUSTAINABILITY
Specifications

Specifications

CD134 (OX40)
Monoclonal
0.2 mg/mL
PBS with BSA and 0.09% sodium azide; pH 7.2
P47741
Tnfrsf4
Affinity chromatography
RUO
22163
4°C, store in dark, DO NOT FREEZE!
Liquid
Flow Cytometry
OX-86
Super Bright 780
Tnfrsf4
ACT35; ACT35 antigen; ATC35 antigen; CD134; CD134 antigen; IMD16; Ly-70; lymphoid activation antigene ACT35; MRC OX40; Ox40; OX40 antigen; OX40 cell surface antigen; OX40 homologue; OX40L receptor; TAX transcriptionally-activated glycoprotein 1 receptor; tax-transcriptionally activated glycoprotein 1; tax-transcriptionally activated glycoprotein 1 receptor; TNF receptor superfamily member 4; Tnfrsf4; tumor necrosis factor (ligand) superfamily member 4; tumor necrosis factor receptor superfamily member 4; tumor necrosis factor receptor superfamily, member 4; tumor necrosis factor superfamily, member 4; Txgp1; Txgp1l
Rat
100 μg
Primary
Mouse
Antibody
IgG1 κ
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Product Certifications
Promotions

Promotions

Product Content Correction

The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.